TipRanks
Advertisement
Advertisement
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
PremiumThe FlyEdgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
2M ago
Edgewise Therapeutics reports Q2 EPS (53c), consensus (47c)
Premium
The Fly
Edgewise Therapeutics reports Q2 EPS (53c), consensus (47c)
3M ago
Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
Premium
Company Announcements
Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors
3M ago
Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4
PremiumThe FlyEdgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4
3M ago
Edgewise Therapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
Edgewise Therapeutics initiated with an Outperform at Oppenheimer
3M ago
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
Premium
The Fly
Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―